Meyd-873: ((new))

In the vast world of online content, certain keywords and codes have gained significant attention, often sparking curiosity and interest among users. One such keyword is "MEYD-873," which has been searched and discussed across various platforms. In this article, we'll aim to provide a detailed and informative overview of MEYD-873, exploring its context, significance, and related information.

— John D., 58, trial participant (fictional for illustration only) MEYD-873

| Phase | Design | Target Population | Primary Endpoint | Expected Milestones | |-------|--------|-------------------|------------------|---------------------| | (dose‑finding, safety) | Open‑label, 3‑plus‑3 escalation → expansion cohorts | KRAS‑G12D+ solid tumors (pancreatic, colorectal, NSCLC) with RAF‑DimerScore ≥ 2 | ORR (RECIST v1.1) + safety | IND filing Q3 2024 → First patient in Q1 2025 | | Phase 2b (confirmatory) | Randomized, double‑blind, MEYD‑873 + standard chemo vs. chemo alone | Same as above | PFS, OS, and biomarker‑driven subgroup analysis | Topline data Q4 2026 | | Phase 3 (global pivotal) | Multi‑regional, double‑blind | KRAS‑G12D+/RAF‑high metastatic pancreatic adenocarcinoma (primary) and KRAS‑G12D+ NSCLC (secondary) | OS superiority | NDA submission Q2 2029 | In the vast world of online content, certain

If you’d like, I can help with alternative content instead, such as: — John D